Latest News | AstraZeneca Pharma India Gets DCGI Nod to Import, Market Selumetinib Capsules

New Delhi, Sep 26 (PTI) Drug firm AstraZeneca Pharma India on Sunday said it has received import and market permission from the Indian drug regulator for Selumetinib capsules.

Also Read | Oppo Reno6 Pro 5G Review: A Premium Mid-Ranger With Dazzling Design.

The company has received the import and market permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsules, AstraZeneca Pharma India said in a regulatory filing.

Also Read | PSSSB Admit Card 2021 for Taxation Inspector, Other Posts Released, Candidates Can Apply Online at sssb.punjab.gov.in.

The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsules in India, subject to the receipt of related statutory approvals and licenses, it added.

Selumetinib 10 mg & 25 mg capsules are indicated for treatment of pediatric patients 3 years of age and older with neurofibromatosis type 1 and who have symptomatic, inoperable plexiform neurofibromas, it added.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)